773 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen https://www.fool.com/investing/2019/12/02/why-novartis-97-billion-purchase-of-the-medicines.aspx?source=iedfolrf0000001 Dec 02, 2019 - Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
Here's Why Merck's (MRK) Shares Are Up This Year http://www.zacks.com/stock/news/644873/heres-why-mercks-mrk-shares-are-up-this-year?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-644873 Nov 28, 2019 - Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer http://www.zacks.com/stock/news/643382/mercks-keytruda-gets-nod-in-china-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-643382 Nov 27, 2019 - Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More http://www.zacks.com/stock/news/643371/biotech-stock-roundup-cbay-falls-ccxi-gains-amgen-acquires-otezla-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-643371 Nov 27, 2019 - Key highlights of the past week include regulatory and pipeline updates.
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
The Medicines Company to be Acquired by Novartis for $9.7B http://www.zacks.com/stock/news/636814/the-medicines-company-to-be-acquired-by-novartis-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636814 Nov 25, 2019 - The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
The Zacks Analyst Blog Highlights: Facebook, Bank of America, Home Depot, Amgen and Intuitive http://www.zacks.com/stock/news/632822/the-zacks-analyst-blog-highlights-facebook-bank-of-america-home-depot-amgen-and-intuitive?cid=CS-ZC-FT-press_releases-632822 Nov 22, 2019 - The Zacks Analyst Blog Highlights: Facebook, Bank of America, Home Depot, Amgen and Intuitive
Top Stock Reports for Facebook, Bank of America & Home Depot http://www.zacks.com/research-daily/631034/top-stock-reports-for-facebook-bank-of-america-home-depot?cid=CS-ZC-FT-research_daily-631034 Nov 21, 2019 - Top Stock Reports for Facebook, Bank of America & Home Depot
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/631099/mercks-keytruda-wins-eu-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631099 Nov 21, 2019 - Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.

Pages: 123456...78

Page 1>